Market Overview

Galapagos Notches $3.95B Upfront Investment From Gilead

Share:
Galapagos Notches $3.95B Upfront Investment From Gilead

Galapagos NV/S ADR (NASDAQ: GLPG) shares were trading higher Monday after the company announced it has entered into a research and development collaboration with Gilead Sciences, Inc. (NASDAQ: GILD). 

Gilead said it will make a $3.95-billion upfront payment and $1.1-billion equity investment in the Belgian pharmaceutical company, according to a Sunday press release. Galapagos intends to use the proceeds to expand its research and development programs.

Gilead will also receive an exclusive product license and option rights to develop and commercialize all current and future programs in all countries outside Europe.

As part of a 10-year global research and development collaboration; Gilead will have access to a portfolio of compounds, including six molecules in clinical trials, more than 20 preclinical programs and a drug discovery platform.

"We chose to partner with Galapagos because of its pioneering target and drug discovery platform, proven scientific capabilities and outstanding team," Gilead CEO Daniel O'Day said in a statement. 

Galapagos shares were trading higher by 16.34% at $169.56 at the time of publication. Gilead shares were trading up by 1.66% at $67.36. 

Related Links:

Zosano Pharma Presents Positive Migraine-ACT Results

Callon Petroleum To Acquire Carrizo In All Stock Deal

 

Related Articles (GILD + GLPG)

View Comments and Join the Discussion!

Posted-In: Biotech News Health Care Contracts General Best of Benzinga

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com